Clinical Reviews in Allergy & Immunology

, Volume 29, Issue 3, pp 213–217 | Cite as

Toward molecular targeting with specific intravenous immunoglobulin preparation

  • Miri Blank
  • Israel Nur
  • Orgad Toub
  • Anabel Maor
  • Yehuda Shoenfeld
Article

Abstract

Intravenous immunoglobulin (IVIg) is used successfully for therapy of inflammatory and autoimmune diseases, especially in cases of conventional therapy resistance. Within the broad spectrum of immunomoregulatory activities of IVIg in vitro and in vivo, the anti-idiotypic activity neutralizing the related idiotypes is one of the main mechanisms. Futhermore, IVIg addresses integrins associated with inflammation and immune response thrombosis, such as the RGD (Arg-Gly-Asp) motif, expressed on a large number of cell surface and matrix proteins. In addition, during the last years, anti-Fas activity of IVIg was reported.

We fractionated IVIg specific preparation (sIVIg) based on the multispecificites of the IVIg compound. We have generated an IVIg fraction that will show specific activity for lupus idiotypes in vitro. In NZBxW.F1 mice, results showed 200 times more beneficial effect. Using a peptide phage display library technology, we have identified a panel of lupus-related synthetic idiotypes that are mimetics of the idiotypes presented in patients with systemic lupus erythematosus. A column composed of these synthetic lupus-related idiotypes was used to prepare a large amount lupus-specific IVIg. Using the same approach, we prepared anti-anti-β-2-glycoprotein-I (β2GPI) specific IVIg for antiphospholipid syndrome (APS). This APS-specific IVIg reduced the fetal loss induced by anti-β2GPI antibodies by improving the implantation process in a mouse model. Others prepared specific preparation of IVIg to RGD or for Fas.

The molecular targeting with specific IVIg may be used for therapeutical purposes, using a smaller amount of IVIg, and targeting more specifically autoimmune diseases, thrombosis, or inflammatory condition.

Index Entries

IVIg anti-idiotype SLE animal model RGD Fas 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Dwyer, J. M. (1992), N Engl J Med 326, 107–116.PubMedCrossRefGoogle Scholar
  2. 2.
    Kazatchkine, M. D. and Kaveri, S. V. (2001), N Engl J Med 345, 747–755.PubMedCrossRefGoogle Scholar
  3. 3.
    Bayry, J., Thirion, M., Misra, N., et al. (2003), Neurol Sci 24, S217-S221.PubMedCrossRefGoogle Scholar
  4. 4.
    Fishman, P., Bar-Yehuda, S., and Shoenfeld, Y. (2004), Int J Oncol 21, 875–880.Google Scholar
  5. 5.
    Rossi, F. and Kazatchkine, M. D. (1989), J Immunol 143, 4104–4109.PubMedGoogle Scholar
  6. 6.
    Sultan, Y., Kazatchkine, M. D., Maissoneuve, P., and Nydegger, U. E. (1984), Lancet 2, 765–768.PubMedCrossRefGoogle Scholar
  7. 7.
    Evans, M. J., Suenaga, R., and Abdou, N. I. (1991), J Clin Immunopathol 11, 291–295.CrossRefGoogle Scholar
  8. 8.
    Isenberg, D. A., Shoenfeld, Y., Madaio, M. P., et al. (1984), Lancet 2, 417–422.PubMedCrossRefGoogle Scholar
  9. 9.
    Isenberg, D. A., Shoenfeld, Y., Walport, M., et al. (1985), Arthritis Rheum 28, 999–1007.PubMedCrossRefGoogle Scholar
  10. 10.
    Rossi, F., Jayne, D. R., Lockwood, C. M., and Kazatchkine, M. D. (1991), Clin Exp Immunol 83, 298–303.PubMedCrossRefGoogle Scholar
  11. 11.
    Tandon, N., Jayne, D. R., McGregor, A. M., and Weetman, A. P. (1992), J Autoimmun 5, 557–570.PubMedCrossRefGoogle Scholar
  12. 12.
    Lundkvist, I., van Doorn, P. A., Vermeulen, M., and Brand, A. (1993), Clin Immunol Immunopathol 67, 192–198.PubMedCrossRefGoogle Scholar
  13. 13.
    Caccavo, D., Vaccaro, F., Ferri, G. M., Amoroso, A., and Bonomo, L. (1994), J Autoimmun 7, 537–548.PubMedCrossRefGoogle Scholar
  14. 14.
    Mehta, Y. S. and Badakere, S. S. (1996), J Postgrad Med 42, 46–49.PubMedGoogle Scholar
  15. 15.
    DeKeyser, F., DeKeyser, H., Kazatchkine, M. D., Rossi, F., Dang, H., and Talal, N. (1996), Clin Exp Rheumatol 14, 587–591.PubMedGoogle Scholar
  16. 16.
    Yuki, N. and Miyagi, F. (1996), J Neurol Sci 139, 160–162.PubMedCrossRefGoogle Scholar
  17. 17.
    Silvestris, F., Cafforio, P., and Dammacco, F. (1994), Clin Exp Immunol 97, 19–25.PubMedCrossRefGoogle Scholar
  18. 18.
    Evans, M. and Abdou, N. I. (1993), Lupus 2, 371–375.PubMedCrossRefGoogle Scholar
  19. 19.
    Blank, M., Manosroi, J., Tomer, Y., Manosroi, A., Kopolovic, J., Charcon-Polak, S., Shoenfeld, Y. (1994), Clin Exp Immunol 98, 434–441.PubMedCrossRefGoogle Scholar
  20. 20.
    Krause, I., Blank, M., Levi, Y., Koike, T., Barak, V., Shoenfeld, Y. (1999), Clin Exp Immunol 117, 190–197.PubMedCrossRefGoogle Scholar
  21. 21.
    Sherer, Y., Gorstein, A., Fritzler, M. J., Shoenfeld, Y. (2004), Semin Arthritis Rheum 34, 501–537.PubMedCrossRefGoogle Scholar
  22. 22.
    Shoenfeld, Y., Rauova, L., Gilburd, B., Kvapil, F., Goldberg, I., Kopolovic, J., Rovensky, J., Blank, M. (2002), Int Immunol 14, 1303–1311.PubMedCrossRefGoogle Scholar
  23. 23.
    Krause, I., Blank, M., Sherer, Y., Gilburd, B., Kvapil, F., Shoenfeld, Y. (2002), Eur J Immunol 32, 3414–3424.PubMedGoogle Scholar
  24. 24.
    Bakimer, R., Guilburd, B., Zurgil, N., Shoenfeld, Y. (1993), Clin Immunol Immunopathol 69, 97–102.PubMedCrossRefGoogle Scholar
  25. 25.
    Ruoslahti, E. and Pierschbacher, M. D. (1987), Science 238, 491–493.PubMedCrossRefGoogle Scholar
  26. 26.
    Levesque, J. P., Hatzfeld, A, Hatzfeld, J. (1991), Immunol Today 12, 258–264.PubMedCrossRefGoogle Scholar
  27. 27.
    Vassilev, T. L., Kazatchkine, M. D., VanHuyen, J. P. D., et al. (1999), Blood 93, 3624–3631.PubMedGoogle Scholar
  28. 28.
    Akiyama, S. K., Olden, K., Yamada, K. M. (1995), Cancer Metastasis Rev 14, 173–178.PubMedCrossRefGoogle Scholar
  29. 29.
    Prasad, N. K., Papoff, G., Zeuner, A., Bonnin, E., Kazatchkine, M. D., Ruberti, G., Kaveri, S. V. (1998), J Immunol 161, 3781–3790.PubMedGoogle Scholar

Copyright information

© Humana Press Inc 2005

Authors and Affiliations

  • Miri Blank
    • 1
    • 2
  • Israel Nur
    • 3
  • Orgad Toub
    • 3
  • Anabel Maor
    • 1
    • 2
  • Yehuda Shoenfeld
    • 1
    • 4
    • 2
  1. 1.Department of Medicine ‘B’ and The Center for Autoimmune DiseasesSheba Medical CenterTel-HashomerIsrael
  2. 2.The Sackler School of MedicineTel Aviv UniversityTel AvivIsrael
  3. 3.OMRIX Biopharmaceuticals Inc.Nes-ZionaIsrael
  4. 4.Incumbent of the Laura Schwarz-Kipp Chair for Research of Autoimmune DiseasesTel Aviv UniversityTel AvivIsrael

Personalised recommendations